Financial Data and Key Metrics Changes - For the quarter ended September 30th, core net investment income was $0.28 per share, with GAAP net investment income also at $0.28 per share [5][16] - Net asset value (NAV) decreased by 1.2% to $10.83 per share from $10.96 per share in the previous quarter [16] - The debt to equity ratio was reported at 1.6 times, which was reduced to 1.4 times after subsequent asset sales [16][17] Business Line Data and Key Metrics Changes - The portfolio grew to $2.8 billion, up from $2.4 billion in the prior quarter, with a weighted average yield on debt investments at 10.2% [12][17] - The portfolio consists of 90% first lien senior secured debt, with only 0.4% of the portfolio in non-accrual status [10][17] - The company invested $633 million in 11 new and 105 existing portfolio companies during the quarter, achieving a weighted average yield of 10.5% [13] Market Data and Key Metrics Changes - The pricing on high-quality first lien term loans is reported at SOFR plus 475-525 basis points, with leverage ratios remaining reasonable [8][9] - The company noted a steady increase in transaction activity in the private middle market lending sector, which is expected to lead to higher loan origination volumes [8] Company Strategy and Development Direction - The company is focused on enhancing earnings power through scale, diversification, and disciplined capital deployment, as evidenced by a $250 million portfolio acquisition and the formation of a new joint venture [5][6] - The goal is to grow the new joint venture, PSSL2, to over $1 billion in assets, similar to existing joint ventures [7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the current market environment, highlighting strong private equity sponsor relationships and disciplined underwriting as key advantages [8] - The company anticipates that the increase in transaction activity will provide opportunities to exit some equity co-investments and reinvest in income-producing assets [8] Other Important Information - The company has a strong credit quality track record, with a loss ratio on invested capital of only 11 basis points annually since inception [12] - The sectors targeted for investment include business services, consumer, government services and defense, healthcare, and software and technology, which are considered recession resilient [10][11] Q&A Session Summary Question: How did the portfolio acquisition come about? - The acquisition was part of a joint venture with a third party, involving assets that were well-known and originated by the company [21][22] Question: Are there more opportunities like the portfolio acquisition? - The company is optimistic about future opportunities, particularly in sectors where they have existing relationships and expertise [21] Question: What impact did the government shutdown have on portfolio companies? - The company has minimal exposure to civilian government activities, focusing more on defense and intelligence, which were not impacted by the shutdown [24] Question: What is the NII contribution from the sold assets? - The NII contribution from the $310 million of assets sold is expected to ramp up over the next year or two as the new joint venture scales [29][30] Question: How does the current leverage ratio cover the dividend? - The company believes that a leverage ratio of 1.5 should easily cover the dividend, even with potential reductions in SOFR [43] Question: What trends are seen in the underlying portfolio companies? - The company is observing double-digit revenue growth and single-digit EBITDA growth across its portfolio, with a healthy overall portfolio despite some choppier credits [46][47] Question: Any consideration for buybacks given the stock price is below book value? - The board considers all options, including buybacks, especially given the current valuation [59]

Financial Data and Key Metrics Changes - Loans held for investment increased by $83 million, or 0.6% linked quarter, and $448 million, or 3.4% year-over-year [5] - Deposit base grew by $550 million, or 3.4% linked quarter, with non-interest-bearing deposits increasing by 5.9% linked quarter [5] - Net income for the third quarter was $56.8 million, representing fully diluted EPS of $0.94, up 2.2% from the prior quarter and 11.9% from the prior year [5][6] - Return on average assets was 1.21% and return on average tangible equity was 12.84% [6] - Net interest income expanded by 2.4% to $165.2 million, with a net interest margin of 3.83%, an increase of two basis points from the prior quarter [6] Business Line Data and Key Metrics Changes - Credit quality remained solid with net charge-offs of $4.4 million, representing 13 basis points of average loans [7] - Non-interest income totaled $39.9 million, up 0.1% linked quarter and 6.3% year-over-year [6] - Non-interest expense increased by $5.8 million, or 4.7% linked quarter, including approximately $2.3 million in non-routine items [6] Market Data and Key Metrics Changes - The company reported diversified loan growth led by commercial and industrial loans, municipal loans, and other real estate secured loans [5] - The total cost of deposits increased by 1.84%, or four basis points linked quarter [5] Company Strategy and Development Direction - The company is focused on organic growth initiatives and enhancing financial performance through hiring in key markets [4][10] - The guidance for loans held for investment is expected to increase mid-single digits for the full year 2025, with low single-digit growth in deposits [9] - The company plans to maintain a disciplined approach to capital deployment, focusing on organic loan growth and potential market expansion [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining momentum and improving financial performance, particularly in key growth markets [10][28] - The company anticipates a continued trend of lower provisions for credit losses compared to the full year 2024 [9] - Management acknowledged the competitive landscape but sees M&A activity as an opportunity for growth [23][29] Other Important Information - The company repurchased $11 million of common stock during the quarter, with a total of $37 million repurchased in the first nine months of the year [8] - The board declared a quarterly cash dividend of $0.24 per share, payable December 15 [8] Q&A Session Summary Question: Can you provide details on recent hiring and future plans? - The company hired approximately 29 new associates in the third quarter, with a focus on key markets like Houston and Atlanta [13][14] Question: Will there be an increase in expenses due to hiring? - Yes, the company expects incremental expense growth related to recent hiring levels [14][15] Question: What are the opportunities for growth in light of recent M&A activity? - Management sees M&A as an opportunity for both hiring and customer acquisition, particularly in competitive markets [22][23] Question: Can you discuss trends in classified and criticized loans? - There was a positive trend with a decrease of about $49 million in criticized loans this quarter [42] Question: What are the expectations for net interest margin and deposit costs? - The company anticipates maintaining net interest margin in the range of 3.80% to 3.83% and expects deposit costs to decrease [36][50]

Financial Data and Key Metrics Changes - Loans held for investment increased by $83 million, or 0.6% linked quarter, and $448 million, or 3.4% year-over-year [5] - Deposit base grew by $550 million, or 3.4% linked quarter, with non-interest-bearing deposits increasing by 5.9% linked quarter [5] - Net income for the third quarter was $56.8 million, representing fully diluted EPS of $0.94, up 2.2% from the prior quarter and 11.9% from the prior year [5] - Return on average assets was 1.21% and return on average tangible equity was 12.84% [6] - Net interest income expanded by 2.4% to $165.2 million, with a net interest margin of 3.83%, an increase of two basis points from the prior quarter [6][7] - Non-interest income totaled $39.9 million, up 0.1% linked quarter and 6.3% year-over-year [7] - Non-interest expense increased by $5.8 million, or 4.7% linked quarter, including approximately $2.3 million in non-routine items [7] Business Line Data and Key Metrics Changes - The growth in loans was diversified, led by commercial and industrial loans, other loans and leases, municipal loans, and other real estate secured loans [5] - Salaries and employee benefits increased by $3.2 million linked quarter due to annual salary merit increases and the cost of additional customer relationship managers [8] Market Data and Key Metrics Changes - Credit quality remained solid with net charge-offs of $4.4 million, representing 13 basis points of average loans in the third quarter [8] - The allowance for credit losses represents 1.22% of loans held for investment [8] Company Strategy and Development Direction - The company is focused on organic growth initiatives and has added customer relationship managers in key markets [4] - The company plans to continue its disciplined approach to capital deployment, with a preference for organic loan growth and potential market expansion [11] - The company is optimistic about maintaining momentum in financial performance and is focused on key growth markets [11][30] Management's Comments on Operating Environment and Future Outlook - Management expects loans held for investment to increase mid-single digits for the full year 2025 and low single-digit growth in deposits [10] - The provision for credit losses is expected to trend lower compared to the full year 2024 [10] - Management is optimistic about maintaining net interest margin in the range of 3.80% to 3.83% [37][52] Other Important Information - The company repurchased $11 million of common stock during the quarter and has $63 million in repurchase authority for the remainder of the year [9] - The board declared a quarterly cash dividend of $0.24 per share, payable December 15 [9] Q&A Session Summary Question: Can you provide details on hiring and future plans? - The company hired approximately 29 new associates in the third quarter, with a focus on key markets like Houston and Atlanta [14] Question: Will there be an increase in expenses due to hiring? - The company expects a slight increase in expenses due to new hires, with about $400,000 attributed to the additional new hires in the third quarter [16] Question: What are the opportunities from recent M&A activity? - Management sees M&A activity as creating opportunities for hiring and customer acquisition, particularly in competitive markets [25] Question: Can you discuss trends in classified and criticized loans? - There was a decrease of about $49 million in criticized loans this quarter, indicating a positive trend [42] Question: What are the expectations for deposit costs and loan yields? - The company anticipates deposit costs to decrease as the Fed cuts rates, with a beta of about 40% expected [52] Question: How does the company plan to fund its balance sheet? - The company aims to maintain a loan-to-deposit ratio in the mid-80s and is confident in its ability to fund loan growth cost-effectively [66]

Financial Data and Key Metrics Changes - The company reported total revenues of $1.6 billion for the third quarter, representing a growth of 35.4% year-over-year and 3.5% organic growth [6][15] - Adjusted EBITDA margin improved by 170 basis points to 36.6%, and adjusted earnings per share grew over 15% to $1.05 [6][16] - Contingent commissions increased by $46 million, with $12 million attributed to AssuredPartners [15] Business Line Data and Key Metrics Changes - The Retail segment achieved total revenue growth of 37.8%, with organic growth at 2.7% [16] - The Specialty Distribution segment grew total revenues by 30%, with organic growth of 4.6% [18] - The organic growth in Retail was impacted by approximately 1% due to adjustments related to employee benefits incentives [9][10] Market Data and Key Metrics Changes - Commercial insurance pricing remained stable, with rates for most lines similar to the second quarter [7][8] - Medical costs increased by 6%-8%, while pharmacy costs rose over 10% [7] - Rates in the admitted P&C markets were flat to up 5% compared to the prior year [8] Company Strategy and Development Direction - The company aims to enhance its solutions and value to customers through leadership changes and the integration of AssuredPartners [4][5] - The Board of Directors raised the dividend by 10% and expanded share repurchase authorization to $1.5 billion [5] - The company is focused on both organic and inorganic growth, with a strong pipeline for M&A activities [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about economic growth remaining stable, with a cautious bias among business leaders [7][23] - The company anticipates organic growth in the fourth quarter to be similar to the third quarter, influenced by employee benefits adjustments [16][21] - Management noted that the pricing environment for casualty and auto rates is expected to continue increasing [24] Other Important Information - The company generated $1 billion in cash flow from operations in the first nine months of 2025, a 24% increase compared to the same period in 2024 [20] - The effective tax rate for the quarter was 24.7%, remaining flat compared to the prior year [16] Q&A Session Summary Question: Relationship of organic growth to EBITDA margins - Management clarified that organic growth is just one component of margin drivers and should not be directly correlated [29][30] Question: Impact of government shutdown on business - Management acknowledged some businesses are impacted, particularly in specialty and retail segments, but expect revenue to catch up once the government reopens [31][32] Question: Retail organic growth impact - Management explained the 1% impact was due to adjustments in incentive commissions for employee benefits [35][36] Question: Future of admitted vs. E&S markets - Management indicated that while there may be some movement back to admitted markets, the E&S market continues to grow [42] Question: Expectations for property renewal rates - Management expects property renewal rates to remain similar, with potential for some markets to become more aggressive at year-end [53][54]

Financial Data and Key Metrics Changes - The company achieved revenue of $699 million in Q3 2025, resulting in 1% organic growth, with foreign exchange (FX) providing a modest tailwind of approximately 1% [24][26] - Adjusted operating margins were reported at 26.1%, slightly above expectations but down 220 basis points year-over-year due to tariffs, FX, and lower volume leverage [24][25] - Adjusted earnings per share (EPS) for the quarter was $1.18, exceeding the midpoint of guidance by $0.05 [26] Business Line Data and Key Metrics Changes - The signals software business grew 20% organically in the quarter, continuing to be a strong performer with an annual recurring revenue (ARR) of over 40% and a net retention rate of more than 110% [28] - The reproductive health business grew in the mid-single digits, with newborn screening growing in the high single digits [5][30] - The diagnostics segment generated $356 million in revenue, up 3% on a reported basis and 2% organically, with immunodiagnostics declining in the low single digits [29] Market Data and Key Metrics Changes - The Americas experienced low single-digit growth, Europe saw mid-single-digit growth, while Asia declined in the mid-single digits, with China specifically declining in the low teens [27] - The diagnostics business in China faced a decline of over 20%, significantly impacting overall performance [31][90] Company Strategy and Development Direction - The company is focusing on capital deployment through share repurchases, having repurchased approximately 2.3 million shares in Q3, totaling 12.5 million shares since the divestiture [8][26] - The company is optimistic about future performance, anticipating organic growth in the 2% to 4% range for the year, while raising adjusted EPS guidance to $4.90 to $5.00 [9][33] - Strategic partnerships, such as those with Genomics England and Sanofi, are expected to enhance product offerings and market presence [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding improving customer confidence and investment levels in the industry, despite current market stability [4][9] - The company is cautious in its assumptions until sustained improvements in broader industry demand trends are observed [10][18] - Management highlighted the importance of AI in driving productivity and innovation, with several new AI-based products launched [11][12] Other Important Information - The company reported a 6% reduction in scope one and two emissions in 2024 and a 77% employee satisfaction rate [17] - The company received a AAA rating from MSCI, indicating strong performance in ESG metrics [17] Q&A Session Summary Question: Insights on 2026 growth outlook - Management indicated a prudent assumption of 2% to 3% organic growth for 2026, with signs of increasing customer activity, particularly in the pharma sector [36][39] Question: Confidence in maintaining 28% operating margin - Management expressed confidence in achieving a 28% operating margin baseline for 2026, supported by ongoing actions and cost containment initiatives [41][42] Question: Performance of reagents in Q3 - Reagents were reported to be slightly below expectations, with modest declines noted, but underlying lab activity remains strong [78][79] Question: Impact of budget flush in Q4 - A modest seasonal increase in instrument sales is expected in Q4, with some improvement in customer activity levels noted [82] Question: Future of China diagnostics - Management expects continued headwinds in China diagnostics due to DRG impacts, but anticipates a return to low single-digit growth post-anniversary in Q2 2026 [90][92]

Financial Data and Key Metrics Changes - Revenue grew 5% in Q3 to $11.12 billion, with adjusted operating income increasing 9% to $2.59 billion [5][21] - Adjusted operating margin expanded by 100 basis points to 23.3% [5][21] - Adjusted EPS increased by 10% to $5.79 per share [5][20] Business Line Data and Key Metrics Changes - **Pharma and Biotech**: Mid-single-digit growth driven by bioproduction and analytical instruments [6] - **Academic and Government**: Revenue declined in low single digits, showing modest improvement [6] - **Industrial and Applied**: Revenue grew in mid-single digits, led by electron microscopy [6] - **Diagnostics and Healthcare**: Revenue growth improved but remained down low single digits, primarily due to conditions in China [6][25] Market Data and Key Metrics Changes - North America grew low single digits, Europe and Asia-Pacific grew mid-single digits, while China declined mid-single digits [21] - Total company adjusted gross margin was 41.9%, reflecting strong productivity [21] Company Strategy and Development Direction - The growth strategy focuses on high-impact innovation, trusted partner status, and a strong commercial engine [7][10] - Recent innovations include FDA-approved diagnostic tests and new electron microscopes [8][9] - Strategic collaborations, such as with OpenAI and AstraZeneca, aim to enhance product offerings and drive innovation [10][13] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating government policies and reshoring activities in the U.S. [33][34] - The company raised its full-year revenue guidance to $44.1 billion to $44.5 billion and adjusted EPS guidance to $22.60 to $22.86 [17][27] - Management remains optimistic about midterm and long-term growth prospects, expecting organic growth of 3% to 6% [54] Other Important Information - The company completed significant acquisitions, including a filtration and separation business and a sterile fill-finish site, enhancing its capabilities [14][15] - Share repurchases totaled $1 billion in Q3, bringing the total for the year to $3 billion [15][23] Q&A Session Summary Question: Market conditions and customer conversations - Management noted excitement among pharma and biotech customers regarding scientific breakthroughs and confidence in their pipelines [33][34] Question: Academic and government funding outlook - Management indicated a more stable funding environment is expected, despite the ongoing government shutdown adding some uncertainty [37][38] Question: Analytical instruments performance - Growth was driven by strong demand in electron microscopy and chromatography, with expectations for continued momentum [44] Question: Diagnostics in China - Management acknowledged weak conditions in China but noted a modest improvement relative to the previous quarter [45][46] Question: Biopharma demand from small biotech - There was positive momentum in clinical research and early activities in pharma services, indicating a potential reinvestment cycle [66][67] Question: Onshoring impact on capacity and volumes - Management discussed incremental demand from new facilities and equipment, but noted that overall drug volumes would remain stable [73][74]

Financial Data and Key Metrics Changes - Revenue grew 5% in Q3 2025 to $11.12 billion [6][26] - Adjusted operating income increased 9% to $2.59 billion [6][27] - Adjusted operating margin expanded by 100 basis points to 23.3% [6][27] - Adjusted EPS rose 10% to $5.79 per share [6][26] Business Line Data and Key Metrics Changes - **Pharma and Biotech**: Mid single-digit growth, driven by bioproduction and analytical instruments [6][7] - **Academic and Government**: Revenue declined in low single digits, showing slight improvement [7][52] - **Industrial and Applied**: Revenue grew in mid single digits, led by electron microscopy [8][32] - **Diagnostics and Healthcare**: Revenue growth improved but remained down low single digits, primarily due to conditions in China [8][64] Market Data and Key Metrics Changes - North America grew low single digits; Europe and Asia Pacific grew mid single digits; China declined mid single digits [26][27] - Total company adjusted gross margin was 41.9%, up 10 basis points year-over-year [28] Company Strategy and Development Direction - The growth strategy focuses on high-impact innovation, trusted partner status, and a strong commercial engine [9][13] - Collaborations with OpenAI aim to enhance product offerings and operational efficiency [14][15] - Strategic partnerships, such as with AstraZeneca, are intended to drive innovation in life sciences [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating government policies and the potential for reshoring in the pharma sector [46][49] - The company raised its full-year revenue guidance to $44.1 billion to $44.5 billion and adjusted EPS guidance to $22.6 to $22.86 [22][36] Other Important Information - The company repurchased $1 billion of shares in Q3, totaling $3 billion for the year [20][30] - The integration of recent acquisitions is progressing smoothly, with positive early feedback from customers [18][19] Q&A Session Summary Question: Market conditions and customer conversations - Management noted excitement around scientific breakthroughs and confidence in customer pipelines, with a focus on reshoring and navigating government policies [46][49] Question: Academic and government funding outlook - Management indicated a more stable funding environment is expected, despite the government shutdown adding some uncertainty [53][55] Question: Analytical instruments performance - Growth was driven by strong demand in electron microscopy and chromatography, with a positive outlook for the fourth quarter [60][62] Question: Diagnostics in China - Weak conditions were noted in China, but the company remains well-positioned for long-term growth despite current pressures [64][92] Question: 2026 growth outlook - Management remains confident in a 3% to 6% organic growth range, with expectations for improved market conditions over time [68][70] Question: Clinical research business trends - The clinical research business is performing well, with strong authorization rates and innovative approaches to improve drug development efficiency [78][80] Question: Demand from small and emerging biotech - There is a positive trend in demand from small biotech firms, supported by recent M&A activity in the sector [87]

Financial Data and Key Metrics Changes - Banner Corporation reported a net profit available to common shareholders of $53.5 million or $1.54 per diluted share for Q3 2025, an increase from $1.30 per share in Q3 2024 and $1.31 per share in Q2 2025 [4] - Core earnings for Q3 2025 were $67.8 million, up from $62.5 million in the prior quarter and $57.4 million in Q3 2024 [5] - Revenue from core operations was $169 million, compared to $163 million in the prior quarter and $154 million in Q3 2024 [6] - Return on average assets was 1.3% for Q3 2025, reflecting strong core performance [6] Business Line Data and Key Metrics Changes - Loans and core deposits both increased by 4% year-over-year, with core deposits representing 89% of total deposits [7] - Delinquent loans improved to 0.39% of total loans, down from 0.40% a year ago [9] - Adversely classified loans decreased by $16 million quarter-over-quarter, now at 1.49% of total loans [9] Market Data and Key Metrics Changes - The company maintained a strong core deposit base, which proved resilient and loyal [6] - The loan-to-deposit ratio ended the quarter at 84%, indicating ample capacity to add new clients [14] Company Strategy and Development Direction - The overarching goal is to provide a consistent and reliable source of commerce and capital through all economic cycles [4] - The company continues to focus on its supercommunity bank strategy, emphasizing client relationships and core funding [6] - Investments in technology and fraud-related systems are prioritized to enhance scalability and efficiency [47][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage through current market uncertainties due to a strong balance sheet and reputation [5] - The company anticipates solid loan growth in Q4, typically a strong quarter [12] - Management noted that the competitive landscape remains unchanged, with a focus on maintaining underwriting standards despite increased competition [41] Other Important Information - The company announced a 4% increase in the core dividend to $0.50 per common share [7] - Banner was recognized as one of America's 100 best banks and received various accolades for its performance and trustworthiness [8] Q&A Session Summary Question: Inquiry about margin and FHLB payoffs - Management indicated that FHLB advances were paid down halfway through the quarter, with expectations of flat funding costs despite Fed rate cuts [22][24] Question: Capital management and M&A interest - Management expressed confidence in continuing share repurchases and indicated readiness for potential M&A opportunities if they arise [26][28] Question: Deposit growth and pricing strategy - Management noted strong deposit growth driven by seasonal factors and indicated reductions in advertised CD rates following the Fed's rate cut [36] Question: Competitive landscape and loan originations - Management acknowledged a multifaceted decline in originations, attributing it to a strong prior quarter and muted reactions to rate cuts [41][42] Question: Strategic investments and technology - The company is investing heavily in technology to enhance scalability and efficiency, with a focus on fraud prevention and AI integration [47][48]

Core Viewpoint - Goldman Sachs held an investor meeting with HEI, highlighting that factors such as the aerospace aftermarket, market share growth, profit margins, and mergers and acquisitions will drive the company's stock price. Goldman maintains a "Buy" rating with a 12-month target price of $382, representing approximately a 19% upside from the recent closing price of $321.74 [1] Group 1: Capital Deployment - HEI is actively assessing merger and acquisition opportunities, focusing on core commercial aviation and defense businesses, with a net debt/EBITDA ratio of approximately 2.0x, providing ample capacity for acquisitions [2] Group 2: Aerospace Aftermarket - HEI has not observed a slowdown in the commercial aftermarket due to fleet aging, limited new aircraft supply, and sustained flight demand. The company anticipates that aftermarket growth will gradually normalize to about 2x GDP/ASK in the long term, rather than the current 14-15% level [3] Group 3: PMA (Parts Manufacturer Approval) - HEI sells PMA parts at a discount equivalent to 70% of OEM parts pricing, with potential discounts expanding to 50-60% as OEM prices rise. The PMA business is mature in commercial aviation but still in early stages in defense, with opportunities comparable to adding 1-2 large airline customers [4] Group 4: Wencor Integration - HEI continues to realize synergies from the acquisition of Wencor, finding that maintaining Wencor's relative independence allows for significant cross-selling and MRO synergies. This integration is driving higher FSG profit margins due to increased sales of PMA parts [5] Group 5: Profit Margins by Division - HEI reaffirms that FSG's EBIT margin is expected to be around 24% in the medium term, with potential for further upside. Recent margin improvements are attributed to higher defense business volume and PMA-friendly operations. In ETG, margins remain below pre-pandemic levels but are expected to expand in the future [6][7]

Core Insights - The company has focused on returning to basics, emphasizing accountability, agility, and innovation to improve business performance [1] - Progress has been made in three key priorities: top line growth through innovation and commercial excellence, operational performance, and effective capital deployment [2] Product Innovation - In the first half of the year, the company launched 126 products, which is nearly equivalent to the total of 128 products launched in all of 2023 [2]